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Objective To investigate whether topiramate associated with mild or deep hypothermia in asphyxiated term in-
fants is safe in relation to the short-term outcome.
Study designWe report on 27 consecutive asphyxiated newborns who were treated with whole body hypother-
mia and 27 additional consecutive newborns with hypothermia who were co-treated with oral topiramate, once
a day for 3 consecutive days, at 2 different doses.
ResultsNewbornswere divided in 6 groups according to the depth of hypothermia and the association with higher
or lower topiramate dosage. A statistical comparison of the groups identified some differences in biochemical and
hemodynamic variables, but no adverse effects attributable to topiramate were detected. Therewere no statistically
significant differences in the groups in short-term outcomes, survival rate at discharge, or incidence of pathologic
brain magnetic resonance imaging.
Conclusion Although the number of newborns in this study was limited, the short-term outcome and the safety
data appear to support the evaluation of topiramate in clinical trials to explore its possible additive neuroprotective
action. (J Pediatr 2010;157:361-6).See editorial, p 351 and
related articles, p 367 and p 499N
eonatal hypoxic-ischemic encephalopathy (HIE), caused by perinatal asphyxia, is one of the leading causes of cerebral
palsy, the incidence of which has remained essentially unchanged in recent decades despite improvements in perinatal
practice and neonatal care.1 Topiramate (TPM), an anticonvulsant agent widely used in adults and children,2,3 has mul-
tiple mechanisms of action, including an inhibitory effect on glutamate receptors. TPM has neuroprotective properties against
hypoxic ischemic brain damage, both in vitro and in animal models, and was included in neuroprotective strategies for ischemic
stroke4-11 and neonatal hypoxic-ischemic cerebral injury.12
Several studies have demonstrated the therapeutic effects of whole-body or selective head cooling to treat asphyxiated new-
borns.13-15 Consequently, mild hypothermia is recommended for the treatment of moderate degrees of encephalopathy.1 Deep
hypothermia may also be safe and neuroprotective.16 Although TPM logically would be expected to enhance the neuroprotective
effects of hypothermia in HIE, no trial has tested this combination treatment.1 Hypothermia can reduce drug clearance, thereby
affecting the pharmacokinetics of drugs.17 In an earlier pilot study, we assessed the effects of mild or deep hypothermia on TPM
pharmacokinetics in neonates withHIE.We observed a slow absorption and elimination of TPM.18We now report the safety pro-
file of TPM in neonates treated with hypothermia in a retrospective comparison with newborns treated with hypothermia only.aPTT Activated partial throm
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TPM TopiramateMethodsWe studied asphyxiated newborns admitted in 2 neonatal intensive care units (NICUs; A. Meyer University Children’s Hos-
pital, Florence, Italy, and Carlo Poma Hospital, Mantua, Italy) from November 2004 to August 2009. Newborns admitted
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the historical control group (deep hypothermia [DH] and
mild hypothermia [MH] groups). Newborns admitted sub-
sequently received combined therapy with mild or deep hy-
pothermia and TPM at 2 different doses (deep hypothermia
and high topiramate dose [DH-highTPM], deep hypother-
mia and low topiramate dose [DH-lowTPM], mild hypo-
thermia and high topiramate dose [MH-highTPM], and
mild hypothermia and low topiramate dose [MH-
lowTPM] groups).
Infants were treated with whole-body hypothermia within
6 hours of birth, and it was continued for 72 hours when these
criteria were fulfilled: (1) gestational age$36 weeks and birth
weigh$1800 g with at least 1 of the following: a) Apgar score
#5 at 10minutes; b) persisting need for resuscitation, includ-
ing endotracheal intubation or mask ventilation 10 minutes
after birth; c) acidosis (pH <7.0, base deficit $16 mmol/L
in umbilical cord blood, or in umbilical cord blood or arte-
rial, venous or capillary blood arterial, venous, or capillary
blood) within 60 minutes from birth; (2) moderate to severe
encephalopathy, consisting of altered state of consciousness
(irritability, lethargy, stupor, or coma) and$1 of the follow-
ing signs: a) hypotonia, b) abnormal reflexes, including ocu-
lomotor or pupil abnormalities, c) absent or weak suck, d)
clinical seizures. Exclusion criteria were congenital abnor-
malities, congenital viral infections, or evidence encephalop-
athy other than HIE. Outborn patients were initially cooled
to 35C at the birth hospital, avoiding heating and using ice
packs during the transfer to NICU.
In 1 of the 2 centers (Mantua), neonates were cooled by ap-
plying ice packs to the head and body or by using a cooling
blanket (NIG 2, Iemmi Medical Srl, Mantua, Italy). In the
other center (Florence), a cooling blanket (Blanketrol III,
Hyper-Hypothermia System, Cincinnati Sub-Zero, Cincin-
nati, Ohio) with an esophageal probe was used to induce
hypothermia; the esophageal temperature was lowered with
the blanket’s servomechanism. Rectal temperature was mon-
itored with a rectal probe connected to cardiomonitor
(Viridia 24C, Hewlett-Packard Company, Palo Alto, Califor-
nia or Infinity Delta, Dra¨ger Medical System, Telford,
Pennsylvania). After 72 hours of hypothermia, the newborns
were gradually re-warmed to 36.5 to 37.0C for 6 to 12 hours
(0.5C/h). Vital signs were continuously monitored during
hypothermia.
TPM was administered with an orogastric tube as enteric-
coated granules mixed with water on arrival in the NICU,
when the cooling was begun (T0), once a day for the first 3
days of life, for a total of 3 doses per patient. Initially, new-
borns received 5 mg/kg once a day (in the DH-highTPM
and the MH-highTPM groups). This schedule was validated
by monitoring that TPM plasma levels were maintained at
the upper limits of the reference range.18 Subsequently, new-
borns received 5 mg/kg on the first day and 3 mg/kg on the
following 2 days, to have lower TPM plasma values (in the
DH-lowTPM and the MH-lowTPM groups). TPM plasma
concentrations were measured on dried blood spots, as pre-
viously reported.18362For the first 9 patients, plasma TPM concentrations were
evaluated starting from 48 hours of hypothermia, before
the administration of the third dose of TPM (T48) and at
T48.5, T49, T49.5, T50, T52, T54, T56, T60, T64, T68, and T72. To
better define drug levels, in the following 18 patients plasma
TPM concentrations were measured at the beginning of hy-
pothermia, before the first dose of TPM (T0), and at T0.5,
T1, T1.5, T2, T4, T6, T8, T12, T16, T20, and T24 (before the sec-
ond dose), at T26, T30, T34, T40, and T48 (before the third
dose), and at T48.5, T49, T49.5, T50, T52, T54, T56, T60, T64,
T68, and T72. In 5 newborns treated with MH-highTPM, con-
centrations were also measured after 12 and 24 hours of
heating.
Respiratory and hemodynamic variables (respiratory rate,
oxygen saturation, fractional inspired oxygen, systolic, dia-
stolic and mean arterial pressures, heart rate) were recorded
before hypothermia and then at hours 0, 6, 12, 18, 24, 30, 36,
42, 48, 54, 60, 66, and 72 of hypothermia, and after re-
warming. These blood tests were planned at T0, T24, T48,
and T72 and 24 hours after re-warming process (T96): blood
gas analysis (corrected for body temperature), serum electro-
lyte level, liver and renal function tests, creatine-kinase level,
creatine-kinase MB isoenzyme level, lactate dehydrogenase
level, troponin IC level, complete cell blood count, C-reactive
protein level, procalcitonin level, and coagulation tests. To
evaluate whether TPM can modify the cellular oxidation re-
duction potential through the inhibition of carbonic anhy-
drase isoenzymes,19 we performed at 24 and 48 hours of
hypothermia, respectively (after 1 and 2 doses of TPM), a re-
dox status study with measurements of plasma lactate, pyru-
vate, ß-hydroxybutyrate, and acetoacetate levels on
deproteinized arterial blood with spectrophotometric assay
(COBAS FARA; Roche, Basel, Switzerland).20
Clinical Course and Concomitant Treatments
A central venous line was placed in all patients. Fluid intake
was started at 60 to 70 mL/kg and increased by 10 to 20 mL/
kg each day, on the basis of changes in body weight and serum
electrolyte levels. Minimal enteral feeding was allowed with
human milk from the first day of life. In case of respiratory
failure, newborns were supported with patient triggered ven-
tilation. Neonates in whom seizures developed were treated
with phenobarbital (loading dose, 20 mg/kg; followed by
1.5-2.5mg/kg every 12 hours). In case of hypotension, defined
as a mean arterial blood pressure <40 mm Hg, single or mul-
tiple normal saline boluses were administered (10-20mL/kg),
and dopamine, dobutamine, or norepinephrine was progres-
sively added when blood pressure did not increase.
Magnetic Resonance Imaging and Ultrasound
Scanning
Brain magnetic resonance imaging (MRI) was planned
within the first week of life. Brain lesions were classified as
isolated lesions of white matter, basal ganglia, and thalamus
with or without involvement of posterior limb of the internal
capsule, cortex, or various combinations of the earlier le-
sions.21 Ultrasound scanning of the abdomen, for detectionFilippi et al
September 2010 ORIGINAL ARTICLESof renal stones and ophthalmologic assessment of the ante-
rior eye segment, was performed within the first week of life.
Statistical Analysis
We tested 5 groups including at least 5 neonates each, but not
including 1 neonate who was given the DH-lowTPM regi-
men. The variables investigated were continuous or categor-
ical. The results were expressed as numbers (percentages) for
categorical variables, as means plus or minus SD for contin-
uous normally distributed data, and as medians and ranges
for non-normally distributed data. For non-normally distrib-
uted data, comparisons were performed with the Kruskal–
Wallis test. This test can be applied when the underlying
population distributions are unknown, and it requires a min-
imum of 5 subjects per group. It addresses the null hypothesis
that there is no treatment effect against the general alternative
hypothesis that at least 2 treatment effects are not equal.22,23
To assess the possible dependence in the different treatments
and the dichotomous variables, the c2 test for k  2 tables
was used. The null hypothesis was accepted with a P value
>.05.23 The Kruskal-Wallis tests were performed with the
Statistical Software Program.24 Dichotomous variables were
processed with a public domain epidemiologic analysis pro-
gram (Epi Info, version 6.01; Centers for Disease Control and
Prevention, Atlanta, Georgia). The study was approved by
the local ethics committees. Written informed consent was
obtained from both parents of all enrolled newborns.
Results
Four newborns (2 treated with hypothermia only and 2
treated with MH-highTPM dose) were not included in the
analysis because the data were incomplete; 1 newborn with
a congenital inborn error of respiratory chain was also ex-
cluded. Newborns reported in an earlier study were in-
cluded.18 Twenty-seven newborns were treated with whole-
body hypothermia only (15 on DH, and 12 on MH). Of
the 27 additional newborns treated with TPM and hypother-
mia, 10 constituted the DH-highTPM group, 1 constituted
the DH-lowTPM group, 6 constituted the MH-highTPM
group, and 10 constituted the MH-lowTPM group. Demo-
graphic and obstetric data are shown in Table I.
Respiratory assistance, hemodynamic support, and numberTable I. Demographic and clinical characteristics at admissio
DH (n = 15) MH (n = 12)
Male, n (%) 9 (60.0) 4 (33.3)
Gestational age, days, mean  SD* 276  14 274  18
Birth weight, g, mean  SD 3247  516 3368  768
Cesarean section, n (%) 7 (46.7) 7 (58.3)
Stained amniotic fluid, n (%) 5 (33.3) 6 (50.0)
Outborn, n (%) 9 (60.0) 8 (66.7)
Apgar score, 1 min, mean  SD 2.7  2.0 3.7  1.8
Apgar score, 5 min, mean  SD 4.9  1.9 5.7  1.5
CRIB score44, mean  SD 3.5  1.2 3.4  1.7
Hr hypothermia started, mean  SD 3.1  1.8 2.8  1.1
*Calculated from maternal menstrual history, from obstetrical data, or with Ballard’s score.
Oral Topiramate in Neonates with Hypoxic Ischemic Encephalopof neonates treated with phenobarbital are presented in
Table II.
Plasma TPM concentrations were measured from the be-
ginning of hypothermia, before the first dose of TPM (T0),
in 4 newborns in the DH-highTPM group, in the newborn
treated with DH-lowTPM, in 3 newborns in the MH-
highTPM group, and in all 10 newborns in the MH-
lowTPM group. For all the remaining newborns, TPM levels
were measured starting from T48 (immediately before the
third dose; Figure). The Figure also reports TPM
concentrations after 12 and 24 hours of re-warming
measured in 5 newborns of the MH-highTPM group.
Two newborns in the DH group, 1 newborn in the DH-
highTPM group, and 1 newborn in MH-lowTPM group
died during the hospitalization. With the c2 test, the hypoth-
esis of contingency between mortality and treatment was
rejected (P= .61). The statistical analysis of themeasured var-
iables (biochemical, hemodynamic, and respiratory) showed
no significant differences in the 5 groups before the begin-
ning of hypothermia. During hypothermia, only the variables
reported in Table IIIwere statistically different with Kruskal-
Wallis tests. After 1 day of hypothermia, pH, base excess, and
bicarbonate levels were lower in the DH and DH-highTPM
groups. However, in the following days these differences
disappeared, and no consistent metabolic acidosis was
detected in newborns with TPM and hypothermia. For
coagulation profile, after one day of hypothermia, activated
partial thromboplastin time (aPTT) and D-dimer levels
were higher in the DH group, and the fibrinogen level was
lower in the DH and DH-highTPM group. These
differences persisted for the second and third day of
treatment, but were not present after 1 day of re-warming.
Systemic arterial pressure values were different in the 5
groups at T6, 12, and 72 and after re-warming, with higher
values for the MH-highTPM and MH-lowTPM groups.
The comparison of the redox status after 24 and 48 hours
of hypothermia was not different (Kruskal-Wallis test).
However, a decrease of lactate and pyruvate levels from 24
to 48 hours (with stable and normal lactate to pyruvate
ratio) was observed in all groups.
With ultrasound scanning of the abdomen, no kidney stones
were revealed. The results of ophthalmologic evaluations, per-
formed in 13 newborns in theDHgroup, in 11 newborns in then of newborns in all subgroups
DH-highTPM
(n = 10)
DH-lowTPM
(n = 1)
MH-highTPM
(n = 6)
MH-lowTPM
(n = 10)
6 (60.0) 1 (100.0) 4 (66.7) 5 (50.0)
275  13 278 283  6 272  14
3294  793 3030 3645  508 2927  550
5 (50.0) 0 (0.0) 4 (66.7) 6 (60.0)
3 (30.0) 1 (100.0) 4 (66.7) 5 (50.0)
7 (70.0) 0 (0.0) 6 (100.0) 9 (90.0)
2.9  2.1 4 1.8  1.7 2.6  1.9
4.6  2.3 7 2.8  2.2 4.7  1.9
4.1  1.6 2 3.2  0.8 5.2  2..9
3.6  1.9 1 4.0  1.4 3.3  1.2
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Table II. Respiratory assistance and pharmacologic support of infants in all subgroups
DH (n = 15) MH (n = 12)
DH-highTPM
(n = 10)
DH-lowTPM
(n = 1)
MH-highTPM
(n = 6)
MH-lowTPM
(n = 10)
Mechanical ventilation, n (%) 12 (80.0) 5 (41.7) 7 (70.0) 1 (100.0) 5 (83.3) 8 (80.0)
Hours of ventilation, median (range) 41 (9-246) 96 (4-194) 123 (3-288) 19 96 (77-142) 86 (24-288)
Oxygen supplementation 12 (80.0) 3 (25.0) 5 (50.0) 1 (100.0) 4 (66.7) 6 (60.0)
Hours of oxygen supplementation, median (range) 62 (4-350) 218 (85-300) 106 (3-288) 10 40 (10-70) 31 (6-174)
Dopamine infusion, n (%) 7 (46.7) 6 (50.0) 3 (30.0) 0 (0) 4 (66.7) 7 (70.0)
Days of dopamine infusion, mean  SD 2.6  0.8 3.2  1.3 4.0  1.0 4.7  1.7 5.2  3.2
Dobutamine infusion, n (%) 6 (40.0) 4 (33.3) 2 (20.0) 0 (0) 2 (33.3) 6 (60.0)
Days of Dobutamine infusion, mean  SD 2.3  1.0 2.7  1.7 4.5  0.7 3.5  0.7 6.0  2.9
Treatment with phenobarbital, n (%) 14 (93.3) 9 (75.0) 3 (30.0) 1 (100) 6 (100.0) 9 (90.0)
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all newborns in the other groups, were normal. Cerebral MRI
was performed in 98.1% of the newborns. A higher incidence
of isolated lesions of white matter was observed in the MH
group, of basal ganglia and thalamus plus cortex was observed
in theDH-highTPMgroup, andof isolated lesions of basal gan-
glia and thalamus was observed in the MH-lowTPM group.
However, the statistical comparisons in newborns treated
with or without TPM (c2 test) were not different.
Discussion
HIE is a leading cause of perinatal mortality and severe neu-
rological impairment. It occurs in approximately 2 to 3 new-
borns for every 1000 live births,25 with a mortality rate of
10% for mild HIE and 60% for severe HIE. Approximately
30% of surviving newborns with mild HIE and 100% of sur-
viving newborns with severe HIE have variable degrees of
neurological disability.26 Neuroprotective drugs may
enhance the neuroprotective properties of hypothermia for
the treatment of HIE.1 However, there are no studies in as-
phyxiated newborns.Figure. Plasma TPM concentrations in newborns treated with A
lowTPM. The grey area represents the TPM reference range.
364TPM is an anti-glutamataergic drug mainly used for the
treatment of epilepsy, 2,3 which has neuroprotective properties.
In neuronal cultures, cell damage induced by oxygen-glucose
deprivation10 or excitotoxic concentrations of glutamate or
kainate27 were consistently attenuated by TPM. In animal
models of cerebral ischemia, TPM reduced the severity of cere-
bral damage either alone5-8 or with hypothermia.9 The neuro-
protective mechanisms of TPM action appear related not only
to glutamate a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA) and kainate receptors inhibition,11,27-30
but also to inhibition of Na+ channels,31 high voltage-
activated calcium currents,4 carbonic anhydrase isoenzymes,32
and mitochondrial permeability transition pore.19 Hypother-
mia, conversely, might enhance post-ischemic glutamate re-
uptake33, and suppress nitric oxide synthase, oxidative stress,
apoptosis, and inflammatory cascades. TPM might therefore
additively act on these pathways.
In neonates with HIE, TPM pharmacokinetic properties
appear to be modified by concomitant hypothermia.18 Sim-
ilarly to other drugs that are poorly metabolized,34 TPM
had reduced clearance with hypothermia, and absorption
and elimination processes were slower.18 Plasma TPM, DH-highTPM B, DH-lowTPM C, MH-highTPM D, and MH-
Filippi et al
Table III. Variables for which Kruskal-Wallis tests were
significant (P < .05) and groups for which a significant
variable difference was found
Variable P value Groups
Blood gas analysis at T24 of hypothermia
pH Y .023 DH, DH-highTPM
BE Y .001 DH, DH-highTPM
HCO3- Y .001 DH, DH-highTPM
Coagulation test at T24 of hypothermia
PTT [ .025 DH
Fibrinogen Y .001 DH, DH-highTPM
D-Dimers [ .001 DH
Coagulation test at T48 of hypothermia
PTT [ .019 DH
Fibrinogen Y .001 DH, DH-highTPM
D-Dimers [ .04 DH
Coagulation test at T72 of hypothermia
PTT [ .016 DH
Fibrinogen Y .014 DH, DH-highTPM
D-Dimers [ .002 DH
Coagulation test after hypothermia
PTT [ .003 DH
D-Dimers [ .031 DH
Blood pressure at T6 of hypothermia
SAP [ .019
MH-lowTPM,
MH-highTPM
DAP [ .016
MH-lowTPM,
MH-highTPM
MAP [ .005
MH-lowTPM,
MH-highTPM
Blood pressure at T12 of hypothermia
SAP [ .022
MH-lowTPM,
MH-highTPM
MAP [ .008
MH-lowTPM,
MH-highTPM
Blood pressure at T72 of hypothermia
SAP [ .006
MH-lowTPM,
MH-highTPM
DAP [ .020
MH-lowTPM,
MH-highTPM
MAP [ .001
MH-lowTPM,
MH-highTPM
Blood pressure after hypothermia
SAP [ .002
MH-lowTPM,
MH-highTPM
DAP [ .019
MH-lowTPM,
MH-highTPM
MAP [ .005
MH-lowTPM,
MH-highTPM
Down and up arrows (Y [) represent variables decreasing or increasing.
BE, Base excess; HCO3
-, bicarbonate; PTT, partial thromboplastin time; SAP, systolic arterial
pressure; DAP, diastolic arterial pressure; MAP, mean arterial pressure.
September 2010 ORIGINAL ARTICLESconcentrations in newborns treated with deep hypothermia
were higher than those of newborns treated with mild hypo-
thermia (Figure).
The safety profile of TPM might be different in neonates
with HIE treated with hypothermia than for adults receiving
chronic therapy for epilepsy. TPM can cause metabolic
acidosis, especially in pediatric patients, because of carbonic
anhydrase inhibition at proximal renal tubule with renal
loss of bicarbonate.35,36 In as many as 48% of adults and
67% of children with epilepsy treated with TPM, a variable
degree of metabolic acidosis develops. However, in most re-
ported cases, bicarbonate levels did not decrease enough to
be clinically significant. Only 11% of patients had serum bi-Oral Topiramate in Neonates with Hypoxic Ischemic Encephalopcarbonate levels <17 mEq/L,35,37 and symptomatic cases
were successfully treated with sodium bicarbonate supple-
mentation.35 Although this observation is reassuring, meta-
bolic acidosis is severe in neonates with HIE, who have
metabolic acidosis because of both asphyxia and renal impair-
ment. In infants, metabolic acidosis usually occurs after 8 to
26 days of TPM treatment, with dosages as high as 8.2 to
26.0 mg/kg/day.38 In our study, there was a mild and revers-
ible acidosis in newborns treated with deep hypothermia.
There was no metabolic acidosis detected in newborns
co-treated with MH and TPM.
Inhibition of a specific mitochondrial isoenzyme of car-
bonic acid anhydrase, as observed after acetazolamide
administration, may induce severe metabolic acidosis
through inhibition of pyruvate carboxylase activity, with
consequent increased lactate to pyruvate ratio and ketosis
with low ß-hydroxybutyrate to acetoacetate ratio.39 In new-
borns treated with hypothermia and TPM, lactate and pyru-
vate levels decreased during treatment, and the lactate to
pyruvate ratio was normal at 24 and 48 hours, thus excluding
impairment of the oxidation reduction status caused by
TPM. Therefore, this short course-low dosages treatment
schedule did not alter acid-base balance. Similar to other car-
bonic acid anhydrase inhibitors, long-course TPM therapy
was associated with increased risk of nephrolitiasis in
adults.35,36 Abdomen ultrasound scanning was performed
in all infants, with no evidence of kidney stones.
Angle closure glaucoma and acute myopia are additional,
although potentially reversible, adverse events related to
TPM treatment in the pediatric age.35,36,40 The results of oph-
thalmological evaluations were normal in these newborns.
Blood chemistry test results showed no relevant differences
in the groups. Hemodynamic variables demonstrated higher
arterial pressure values at T6, 12, and 72 and after re-warming
for newborns in the MH-highTPM and MH-lowTPM
groups. This finding might be caused by a lack of homogene-
ity of the patients. In these 2 groups, the percentage of new-
borns treated with inotropic drugs and the duration of their
use were slightly higher, probably as a consequence of a more
severe hypoxic-ischemia, as suggested by the Apgar scores in
the MH-highTPM group and Clinical Risk Index for Babies
(CRIB) score in the MH-lowTPM group. None of the new-
borns treated with TPM had hypertension (defined as blood
pressure levels persistently >95th percentile for birth weight
and gestational age on the basis of available normative
data).41
Long-term effects on cognitive functions of TPM adminis-
tration in early life remain to be assessed. In asphyxiated an-
imal models treated with TPM, no cognitive deficit was
demonstrated,10 and in epileptic neonate rodents, TPM ap-
pears safer than phenobarbital or benzodiazepines.42,43 Neu-
ronal death occurred at doses of 50 mg/kg, which are
considerably higher than common therapeutic schedules.
The gap between effective and neurotoxic doses is greater
for TPM than for other antiepileptic drugs,43 and short-
course therapy appears to have few neurotoxic effects. nathy Treated with Hypothermia: A Safety Study 365
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